IBDEI1XM ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33935,1,4,0)
 ;;=4^I69.021
 ;;^UTILITY(U,$J,358.3,33935,2)
 ;;=^5007396
 ;;^UTILITY(U,$J,358.3,33936,0)
 ;;=I69.821^^183^2013^31
 ;;^UTILITY(U,$J,358.3,33936,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33936,1,3,0)
 ;;=3^Dysphasia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,33936,1,4,0)
 ;;=4^I69.821
 ;;^UTILITY(U,$J,358.3,33936,2)
 ;;=^5007523
 ;;^UTILITY(U,$J,358.3,33937,0)
 ;;=I69.221^^183^2013^30
 ;;^UTILITY(U,$J,358.3,33937,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33937,1,3,0)
 ;;=3^Dysphasia following oth nontraumatic intracranial hemorrhage
 ;;^UTILITY(U,$J,358.3,33937,1,4,0)
 ;;=4^I69.221
 ;;^UTILITY(U,$J,358.3,33937,2)
 ;;=^5007460
 ;;^UTILITY(U,$J,358.3,33938,0)
 ;;=G11.1^^183^2013^32
 ;;^UTILITY(U,$J,358.3,33938,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33938,1,3,0)
 ;;=3^Early-onset cerebellar ataxia
 ;;^UTILITY(U,$J,358.3,33938,1,4,0)
 ;;=4^G11.1
 ;;^UTILITY(U,$J,358.3,33938,2)
 ;;=^5003753
 ;;^UTILITY(U,$J,358.3,33939,0)
 ;;=I69.392^^183^2013^33
 ;;^UTILITY(U,$J,358.3,33939,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33939,1,3,0)
 ;;=3^Facial weakness following cerebral infarction
 ;;^UTILITY(U,$J,358.3,33939,1,4,0)
 ;;=4^I69.392
 ;;^UTILITY(U,$J,358.3,33939,2)
 ;;=^5007517
 ;;^UTILITY(U,$J,358.3,33940,0)
 ;;=I69.192^^183^2013^34
 ;;^UTILITY(U,$J,358.3,33940,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33940,1,3,0)
 ;;=3^Facial weakness following nontraumatic intcrbl hemorrhage
 ;;^UTILITY(U,$J,358.3,33940,1,4,0)
 ;;=4^I69.192
 ;;^UTILITY(U,$J,358.3,33940,2)
 ;;=^5007454
 ;;^UTILITY(U,$J,358.3,33941,0)
 ;;=I69.292^^183^2013^36
 ;;^UTILITY(U,$J,358.3,33941,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33941,1,3,0)
 ;;=3^Facial weakness following oth nontraumatic intcrn hemorrhage
 ;;^UTILITY(U,$J,358.3,33941,1,4,0)
 ;;=4^I69.292
 ;;^UTILITY(U,$J,358.3,33941,2)
 ;;=^5007486
 ;;^UTILITY(U,$J,358.3,33942,0)
 ;;=I69.092^^183^2013^35
 ;;^UTILITY(U,$J,358.3,33942,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33942,1,3,0)
 ;;=3^Facial weakness following ntrm subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,33942,1,4,0)
 ;;=4^I69.092
 ;;^UTILITY(U,$J,358.3,33942,2)
 ;;=^5007422
 ;;^UTILITY(U,$J,358.3,33943,0)
 ;;=I69.892^^183^2013^37
 ;;^UTILITY(U,$J,358.3,33943,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33943,1,3,0)
 ;;=3^Facial weakness following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,33943,1,4,0)
 ;;=4^I69.892
 ;;^UTILITY(U,$J,358.3,33943,2)
 ;;=^5007548
 ;;^UTILITY(U,$J,358.3,33944,0)
 ;;=I69.351^^183^2013^39
 ;;^UTILITY(U,$J,358.3,33944,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33944,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff right dominant side
 ;;^UTILITY(U,$J,358.3,33944,1,4,0)
 ;;=4^I69.351
 ;;^UTILITY(U,$J,358.3,33944,2)
 ;;=^5007504
 ;;^UTILITY(U,$J,358.3,33945,0)
 ;;=I69.352^^183^2013^38
 ;;^UTILITY(U,$J,358.3,33945,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33945,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff left dominant side
 ;;^UTILITY(U,$J,358.3,33945,1,4,0)
 ;;=4^I69.352
 ;;^UTILITY(U,$J,358.3,33945,2)
 ;;=^5007505
 ;;^UTILITY(U,$J,358.3,33946,0)
 ;;=I69.353^^183^2013^40
 ;;^UTILITY(U,$J,358.3,33946,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33946,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff right nondom side
 ;;^UTILITY(U,$J,358.3,33946,1,4,0)
 ;;=4^I69.353
 ;;^UTILITY(U,$J,358.3,33946,2)
 ;;=^5007506
 ;;^UTILITY(U,$J,358.3,33947,0)
 ;;=I69.354^^183^2013^41
 ;;^UTILITY(U,$J,358.3,33947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33947,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc affecting left nondom side
 ;;
 ;;$END ROU IBDEI1XM
